Bayer announced they will pay over $10 billion to settle around 75% of the current Roundup cancer cases pending against them in the U.S. alleging Roundup weed killer caused users to develop non-Hodgkin’s lymphoma and other cancers. Currently the company faces over 125,000 Roundup injury lawsuits nationwide.
In a statement released June 24, Bayer indicated the settlement payments will range between $8.8 billion and $9.6 billion to resolve the Roundup litigation. They also established a $1.25 billion fund to address future claims brought forward by individuals claiming they were diagnosed with non-Hodgkin’s lymphoma after being exposed to Roundup weed killer.
“First and foremost, the Roundup™ settlement is the right action at the right time for Bayer to bring a long period of uncertainty to an end,” said Werner Baumann, Bayer’s Chief Executive Officer. “It resolves most current claims and puts in place a clear mechanism to manage risks of potential future litigation.”
Plaintiffs involved in the Roundup litigation allege that weed killer’s active ingredient --- glyphosate --- caused them to develop cancer, notably non-Hodgkin’s lymphoma. In 2015 the World Health Organization’s International Agency for Research on Cancer classified glyphosate as “probably carcinogenic to humans,” and many countries have since banned herbicides containing glyphosate, Roundup included.
Even with this massive settlement there will still be around 25,000 unresolved Roundup cancer cases, which may require several billions in additional funding to resolve. Many expect Bayer and their Monsanto subsidiary will face years of lawsuits for failure to warn users about the link between Roundup’s active ingredient and cancer as users find their non-Hodgkin’s lymphoma and other cancers were caused by exposure to Roundup.
Parts of the Roundup settlement are still pending court approval from Judge Vince Chhabria, who oversees the Roundup weed killer litigation in the U.S. District Court for the Northern District of California.